Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 12/20 | 0.52 |
| ▸ | ITGA2B | P08514 | 12/20 | 0.52 |
| ▸ | F2R | P25116 | 4/20 | 0.46 |
| ▸ | YAP1 | P46937 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7502149 | 0.91 | ITGB3 (0.53) | ITGB3ITGA2BF2RYAP1 | |
| SCHEMBL7497489 | 0.88 | ITGB3 (0.48) | ITGB3ITGA2BF2RYAP1 | |
| SCHEMBL7502300 | 0.86 | ITGB3 (0.59) | ITGB3ITGA2BF2R | |
| SCHEMBL6936346 | 0.86 | ITGB3 (0.57) | ITGB3ITGA2BF2RYAP1 | |
| SCHEMBL7501271 | 0.86 | ITGB3 (0.52) | ITGB3ITGA2BF2RYAP1HTT | |
| SCHEMBL7502142 | 0.86 | ITGB3 (0.55) | ITGB3ITGA2BF2RYAP1HTT | |
| SCHEMBL7500520 | 0.84 | ITGB3 (0.55) | ITGB3ITGA2BF2RHTTKDM4E | |
| SCHEMBL13716893 | 0.83 | ITGB3 (0.54) | ITGB3ITGA2BF2R | |
| SCHEMBL6942125 | 0.83 | ITGB3 (0.55) | ITGB3ITGA2BF2RYAP1L3MBTL1 | |
| SCHEMBL6936057 | 0.83 | ITGB3 (0.55) | ITGB3ITGA2BF2RYAP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6380215-B1 | FOR PREVENTION AND/OR TREATMENT OF DISEASES CAUSED BY THROMBUS FORMATION SUCH AS ARTERIAL THROMBOSIS, ARTERIAL SCLEROSIS, ISCHEMIC HEART DISEASES | FUJISAWA PHARMACEUTICAL CO., LTD (JP) | 2002-04-30 | — | — | US | disclosed |
| EP-0669912-B1 | N-(3-PIPERIDINYLCARBONYL)-BETA-ALANINE DERIVATIVES AS PAF ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO (JP) | 2001-12-05 | — | — | EP | disclosed |
| EP-1106606-A2 | N-(3-piperidinylcarbonyl)-beta-alanine derivatives as paf antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-06-13 | — | — | EP | disclosed |
| EP-0669912-A1 | N-(3-PIPERIDINYLCARBONYL)-BETA-ALANINE DERIVATIVES AS PAF ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-09-06 | — | — | EP | disclosed |
| WO-1995008536-A1 | N-(3-PIPERIDINYLCARBONYL)-BETA-ALANINE DERIVATIVES AS PAF ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-03-30 | — | — | WO | disclosed |